Cancer name Multiple Myeloma
Cancer Type MM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Daratumumab
Drugstatus Approved
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature CD38
Official Symbol CD38
Mode of action PROT_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 2
Description Sixteen weeks after the first daratumumab infusion, the MM cells of DRd-treated patients had significantly lower CD38 expression levels, compared to baseline values (medianfluorescence intensity (MFI) CD38: 9220 versus 60516; P= 0.0313) . Similarly, at the time of progression during DRd treatment MM cells had low CD38 expression levels
PMID 29025767
Title Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab